Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations

Diffuse large B cell lymphoma (DLBCL) frequently harbors genetic alterations that activate the B cell receptor (BCR) and TLR pathways, which converge to activate NF-κB. While selective inhibition of BTK with ibrutinib causes clinical responses in relapsed DLBCL patients, most responses are partial a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Mondello, Patrizia, Brea, Elliott J., De Stanchina, Elisa, Toska, Eneda, Chang, Aaron Y., Fennell, Myles, Seshan, Venkatraman, Garippa, Ralph, Scheinberg, David A., Baselga, José, Wendel, Hans-Guido, Younes, Anas
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5358483/
https://ncbi.nlm.nih.gov/pubmed/28352655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.90196
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados